| Title |
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, June 2012
|
| DOI | 10.1007/s10549-012-2114-5 |
| Pubmed ID | |
| Authors |
Caitlin C. Murphy, L. Kay Bartholomew, Melissa Y. Carpentier, Shirley M. Bluethmann, Sally W. Vernon |
| Abstract |
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| United Kingdom | 1 | 33% |
| Canada | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 314 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | <1% |
| Brunei Darussalam | 1 | <1% |
| Brazil | 1 | <1% |
| Slovenia | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 309 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 42 | 13% |
| Researcher | 42 | 13% |
| Student > Master | 35 | 11% |
| Student > Bachelor | 26 | 8% |
| Student > Postgraduate | 23 | 7% |
| Other | 63 | 20% |
| Unknown | 83 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 104 | 33% |
| Psychology | 33 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 20 | 6% |
| Nursing and Health Professions | 13 | 4% |
| Agricultural and Biological Sciences | 10 | 3% |
| Other | 41 | 13% |
| Unknown | 93 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2023.
All research outputs
#733,701
of 24,754,968 outputs
Outputs from Breast Cancer Research and Treatment
#71
of 4,911 outputs
Outputs of similar age
#3,663
of 171,397 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#1
of 43 outputs
Altmetric has tracked 24,754,968 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,911 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 171,397 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.